Hospital

Cemiplimab was also superior in improving progression-free survival, objective response rate, and duration of response in patients with non–small cell lung cancer (NSCLC).

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

A recent study highlights the AOV dual-chamber system as a faster, safer option for RSV vaccine reconstitution, enhancing efficiency for health care providers.

Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.

In a recent study, machine learning demonstrated its ability to predict progression to end-stage renal disease among patients with chronic kidney disease (CKD).

GLP-1 receptor agonists enhance glycemic control and weight management in youth with type 2 diabetes (T2D) and obesity; however, safety concerns persist.

World Lymphoma Day highlights the rising prevalence of lymphoma and innovative treatments, emphasizing the role of pharmacists in patient care.

Research reveals that this population may experience lower short-term mortality rates after major surgery, challenging traditional BMI guidelines.

Research reveals semaglutide's potential to reduce cocaine-seeking behavior in rats, suggesting a promising avenue for treating cocaine dependency in humans.

A panel of 4 experts discussed the most favored nation (MFN) initiative and its impacts on research and development, market and payer distributions, and pharmacists and patients.

The findings were presented at the 2025 American Heart Association Hypertension Scientific Sessions and published in the Journal of the American Society of Nephrology.

Researchers uncover a brain circuit linking stress to increased blood glucose, revealing insights into stress's role in type 2 diabetes (T2D) development.

GLSI-100 shows promise in preventing HER2-positive breast cancer recurrence after standard therapy.

A pharmacist-led initiative enhanced parenteral nutrition practices, improving patient outcomes and workflow efficiency while reducing errors and costs.

The FDA approves a groundbreaking gemcitabine system, offering new hope for patients with BCG-unresponsive bladder cancer.

Investigators emphasize that early cardiovascular risk assessments and preventive strategies are necessary for women with polycystic ovarian syndrome (PCOS).

The 2 abstracts, which were presented at the European Society of Cardiology 2025 Congress, utilized data from the CDC WONDER database.

Experts discuss radon—the second leading cause of lung cancer.

Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).

Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).

RSV vaccination shows promise in reducing cardiorespiratory hospitalizations among older adults, highlighting potential heart and lung health benefits.

Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

A chief pharmacy officer emphasizes the vital role of pharmacists in enhancing patient care, advocating for recognition, and integration within health care systems.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.